


We claim:

1. A compound having the general formula Ib:



wherein

X, Y and Z are CH;

o is 0; n is 0; m is 0, 1, 2, 3 or 4;

A is C=O


W is NH;

R² is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C₁-C₁₀ alkyl, C₃-C₁₀ cycloalkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ haloalkyl, -OH, -OR⁵, C₁-C₁₀ alkoxy, C₃-C₁₀ cycloalkoxy, C₃-C₁₅ cycloalkylalkoxy, C₃-C₁₅ cycloalkylalkyl, -CN, -NO₂, -NH₂, -N(R⁵)₂, -C(O)R⁵, -C(O)OR⁵, -C(O)N(R⁵)₂, -SR⁵, -S(O)R⁵, -S(O)₂R⁵, -S(O)₂N(R⁵)₂, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;

R³ is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C₁-C₁₀ alkyl, C₃-C₁₀ cycloalkyl, hydroxyl, -OR⁶, -CN, -NO₂, -NH₂, -N(R⁶)C(O)R⁶, -C(O)R⁶, -C(O)OR⁶, -C(O)N(R⁶)₂, -S(O)R⁶, -S(O)₂R⁶, -S(O)₂N(R⁶)₂, aryl, e.g. phenyl, benzyl, heteroaryl, heterocyclyl, any of which is optionally substituted, or two groups of R³ are connected to each other to make five or six membered cyclic and heterocyclic rings;

R⁵ and R⁶ are, at each occurrence, independently selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, C₃-C₁₀ cycloalkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;

R¹⁰ is a moiety selected from the group consisting of



wherein m' is 0, 1, 2, 3 or 4 and n' is 0, 1, 2, or 3;


















R^{11} is, at each occurrence, independently selected from the group consisting of hydrogen, C_1 - C_{10} alkyl, C_3 - C_{10} cycloalkyl, C_2 - C_{10} alkenyl, C_3 - C_{10} cycloalkenyl, C_2 - C_{10} alkynyl, C_1 - C_{10} haloalkyl, -OH, -OR¹³, C_1 - C_{10} alkoxy, C_3 - C_{10} cycloalkoxy, C_3 - C_{15} cycloalkylalkoxy, C_3 - C_{15} cycloalkylalkyl, -NH₂, -N(R¹³)₂, -C(O)R¹³, -C(O)OR¹³, -C(O)N(R¹³)₂, -S(O)R¹³, -S(O)₂R¹³, -S(O)₂N(R¹³)₂, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;













R^{12} is, at each occurrence, independently selected from the group consisting of hydrogen, C_1 - C_{10} alkyl, C_3 - C_{10} cycloalkyl, C_2 - C_{10} alkenyl, C_3 - C_{10} cycloalkenyl, C_2 - C_{10} alkynyl, C_1 - C_{10} haloalkyl, hydroxyl, -OR¹⁴, -C(O)R¹⁴, -C(O)OR¹⁴, -CN, -NO₂, -NH₂, -N(R¹⁴)₂, -C(O)N(R¹⁴)₂, -S(O)R¹⁴, -S(O)₂R¹⁴, -S(O)₂N(R¹⁴)₂, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;



R^{13} is, at each occurrence, independently selected from the group consisting of hydrogen, C_1 - C_{10} alkyl, C_3 - C_{10} cycloalkyl, C_2 - C_{10} alkenyl, C_3 - C_{10} cycloalkenyl, C_2 - C_{10} alkynyl, C_1 - C_{10} haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl; and


R^{14} is, at each occurrence, independently selected from the group consisting of hydrogen, C_1 - C_8 alkyl optionally substituted with at least one hydroxyl or halogen; C_3 - C_7 cycloalkyl, C_2 - C_{10} alkenyl, C_3 - C_{10} cycloalkenyl, C_2 - C_{10} alkynyl, C_1 - C_{10} haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl and heterocyclyl.

2. The compound as claimed in claim 1, having one of the formulae 1-352,












164




165




166




167




168




169




170




171




172




173




174




175




176




177




178




179




180




181




183





















193












194




195









265




267




266




268





















269







































270





























271












preferably one of the formulae, 56, 66-69, 74, 77-80, 89-91, 110, 111, 113, 139, 140, 144, 162-167, 171-182, 193, 209-218, 221-225, 267-269, 271-274, 280-293, 295-315, 317-318, 320-321, and 324.

3. A compound having one of the formulae 17, 56, 58, 59, 66-69, 74, 77-80, 89-91, 108-115, 139, 140, 144, 162-181, 183, 193-195, 204-225, 265-329, and 331-352 as shown in claim 2, preferably one of the formulae 56, 66-69, 74, 77-80, 89-91, 110, 111, 113, 139, 140, 144, 162-167, 171-181, 193, 209-218, 221-225, 267-269, 271-274, 280-293, 295-315, 317-318, 320-321, and 324.

4. The compound as claimed in claim 1, having formula 177.

5. A compound having the general formula Ib:



wherein

X, Y and Z are CH;

o is 1; n is 0; m is 1, 2, 3 or 4;

A is C=O;


W is NH;

R² is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C₁-C₁₀ alkyl, C₃-C₁₀ cycloalkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ haloalkyl, -OR⁵, C₁-C₁₀ alkoxy, C₃-C₁₀ cycloalkoxy, C₃-C₁₅ cycloalkylalkoxy, C₃-C₁₅ cycloalkylalkyl, -CN, -NO₂, -NH₂, -N(R⁵)₂, -C(O)R⁵, -C(O)OR⁵, -C(O)N(R⁵)₂, -SR⁵, -S(O)R⁵, -S(O)₂R⁵, -S(O)₂N(R⁵)₂, aryl, e.g. phenyl, benzyl, and heterocyclyl;

R³ is, at each occurrence, independently selected from the group consisting of halogen, C₁-C₁₀ alkyl, C₃-C₁₀ cycloalkyl, hydroxyl, -OR⁶, -CN, -NO₂, -NH₂, -N(R⁶)C(O)R⁶, -C(O)R⁶, -C(O)N(R⁶)₂, -S(O)R⁶, -S(O)₂R⁶, -S(O)₂N(R⁶)₂, aryl, e.g. phenyl, benzyl, heteroaryl, heterocyclyl, or two groups of R³ are connected to each other to make five or six membered cyclic and heterocyclic rings,

R⁵ and R⁶ are, at each occurrence, independently selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, C₃-C₁₀ cycloalkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;

R¹⁰ is a moiety selected from the group consisting of



wherein m' is 0, 1, 2, 3 or 4 and n' is 0, 1, 2, or 3;

R^{11} is, at each occurrence, independently selected from the group consisting of hydrogen, C_1 - C_{10} alkyl, C_3 - C_{10} cycloalkyl, C_2 - C_{10} alkenyl, C_3 - C_{10} cycloalkenyl, C_2 - C_{10} alkynyl, C_1 - C_{10} haloalkyl, -OH, -OR¹³, C_1 - C_{10} alkoxy, C_3 - C_{10} cycloalkoxy, C_3 - C_{15} cycloalkylalkoxy, C_3 - C_{15} cycloalkylalkyl, -NH₂, -N(R¹³)₂, -C(O)R¹³, -C(O)OR¹³, -C(O)N(R¹³)₂, -S(O)R¹³, -S(O)₂R¹³, -S(O)₂N(R¹³)₂, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;

R^{12} is, at each occurrence, independently selected from the group consisting of hydrogen, C_1 - C_{10} alkyl, C_3 - C_{10} cycloalkyl, C_2 - C_{10} alkenyl, C_3 - C_{10} cycloalkenyl, C_2 - C_{10} alkynyl, C_1 - C_{10} haloalkyl, hydroxyl, -OR¹⁴, -C(O)R¹⁴, -CN, -NO₂, -NH₂, -N(R¹⁴)₂, -C(O)N(R¹⁴)₂, -S(O)R¹⁴, -S(O)₂R¹⁴, -S(O)₂N(R¹⁴)₂, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;

R^{13} is, at each occurrence, independently selected from the group consisting of hydrogen, C_1 - C_{10} alkyl, C_3 - C_{10} cycloalkyl, C_2 - C_{10} alkenyl, C_3 - C_{10} cycloalkenyl, C_2 - C_{10} alkynyl, C_1 - C_{10} haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl, and

R^{14} is, at each occurrence, independently selected from the group consisting of hydrogen, C_1 - C_8 alkyl optionally substituted with at least one hydroxyl or halogen; C_3 - C_7 cycloalkyl, C_2 - C_{10} alkenyl, C_3 - C_{10} cycloalkenyl, C_2 - C_{10} alkynyl, C_1 - C_{10} haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl and heterocyclyl.

6. A pharmaceutical composition comprising a compound as claimed in any of claims 1 –5, and a pharmaceutically acceptable carrier.


Dated 10th day of July, 2019



**KAVITA ARORA
OF K & S PARTNERS
AGENT FOR THE APPLICANT(S)
IN/PA-2160**

We claim:

~~1. A compound having the general formula Ia:~~



~~wherein~~

~~m is 0, 1, 2, 3 or 4;~~

~~n is 0, 1, 2, or 3;~~

~~X, Y and Z are CH, N or N-oxide;~~

~~R¹ is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C₁-C₁₀-alkyl, C₁-C₃-haloalkyl, C₃-C₇-cycloalkyl, hydroxyl, oxo, —OR⁴, —C(O)OR⁴, —C(O)R⁴, —C(O)N(R⁴)₂, —CN, —NO₂, —NH₂, —N(R⁴)₂, —OR⁴HetA, —OR⁴N(R⁴)₂, —C(O)N(R⁴)R⁴HetA, —C(O)N(R⁴)HetA, —C(O)HetA, —C(O)N(R⁴)R⁴S(O)₂R⁴, —S(O)₂N(R⁴)₂, —S(O)₂R⁴, —N(R⁴)C(O)R⁴SR⁴, —N(R⁴)R⁴S(O)₂R⁴, —N(R⁴)S(O)₂R⁴, —C(S)R⁴, aryl, e.g. phenyl, benzyl, and heterocyclyl, any of which is optionally substituted;~~

~~R² is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C₁-C₁₀-alkyl, C₃-C₁₀-cycloalkyl, C₂-C₁₀-alkenyl, C₃-C₁₀-cycloalkenyl, C₂-C₁₀-alkynyl, C₁-C₁₀-haloalkyl, —OH, —OR⁵, C₁-C₁₀-alkoxy, C₃-C₁₀-cycloalkoxy, C₃-C₁₅-cycloalkylalkoxy, C₃-C₁₅-cycloalkylalkyl, —CN, —NO₂, —NH₂, —N(R⁵)₂, —C(O)R⁵, —C(O)OR⁵, —C(O)N(R⁵)₂, —SR⁵, —S(O)R⁵, —S(O)₂R⁵, —S(O)₂N(R⁵)₂, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl, any of which is optionally substituted;~~


~~R³ is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C₁-C₁₀-alkyl, C₃-C₁₀-cycloalkyl, hydroxyl, —OR⁶, —CN, —NO₂, —NH₂, —N(R⁶)C(O)R⁶, —C(O)R⁶, —C(O)OR⁶, —C(O)N(R⁶)₂, —S(O)R⁶, —S(O)₂R⁶, —S(O)₂N(R⁶)₂, aryl, e.g. phenyl, benzyl, heteroaryl, heterocyclyl, any of which is optionally substituted, or two groups of R³ are connected to each other to make five or six membered cyclic and heterocyclic rings, any of which is optionally substituted;~~

R^4 is, at each occurrence, independently selected from the group consisting of hydrogen, C_1 - C_{10} alkyl, C_3 - C_{10} cycloalkyl, C_2 - C_{10} alkenyl, C_3 - C_{10} cycloalkenyl, C_2 - C_{10} alkynyl, C_4 - C_{10} haloalkyl, $-C(O)R^7$, $-R^7(R^7)C(O)R^7$, $-C(O)OR^7$, $-R^7(R^7)C(O)OR^7$, $-C(O)N(R^7)_2$, $-R^7(R^7)C(O)N(R^7)_2$, $-S(O)R^7$, $-S(O)_2R^7$, $-S(O)_2N(R^7)_2$, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl, any of which is optionally substituted; and

R^5 , R^6 and R^7 are, at each occurrence, independently selected from the group consisting of hydrogen, C_1 - C_{10} alkyl, C_3 - C_{10} cycloalkyl, C_2 - C_{10} alkenyl, C_3 - C_{10} cycloalkenyl, C_2 - C_{10} alkynyl, C_4 - C_{10} haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl, any of which is optionally substituted;

and pharmaceutically acceptable salts thereof.

21. The A compound according to claim 1, having the general formula Ib:




wherein

X, Y and Z are CH;

o is 0, 1, 2, or 3; n is 0, 1, 2 or 3; m is 0, 1, 2, 3 or 4;

A is $-NR^{++}$, $C=O$, $C=S$, $OP(O)$, $P=O$, CH_2 , or a heteroaryl selected from the group consisting of



W is $NH-C=O$, O , S , CH_2 or NR^{++} ;


R^2 is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C_1 - C_{10} alkyl, C_3 - C_{10} cycloalkyl, C_2 - C_{10} alkenyl, C_3 - C_{10} cycloalkenyl, C_2 - C_{10} alkynyl, C_1 - C_{10} haloalkyl, $-OH$, $-OR^5$, C_1 - C_{10} alkoxy, C_3 - C_{10} cycloalkoxy, C_3 - C_{15} cycloalkylalkoxy,

C₃-C₁₅ cycloalkylalkyl, -CN, -NO₂, -NH₂, -N(R⁵)₂, -C(O)R⁵, -C(O)OR⁵, -C(O)N(R⁵)₂, -SR⁵, -S(O)R⁵, -S(O)₂R⁵, -S(O)₂N(R⁵)₂, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;

R³ is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C₁-C₁₀ alkyl, C₃-C₁₀ cycloalkyl, hydroxyl, -OR⁶, -CN, -NO₂, -NH₂, -N(R⁶)C(O)R⁶, -C(O)R⁶, -C(O)OR⁶, -C(O)N(R⁶)₂, -S(O)R⁶, -S(O)₂R⁶, -S(O)₂N(R⁶)₂, aryl, e.g. phenyl, benzyl, heteroaryl, heterocyclyl, any of which is optionally substituted, or two groups of R³ are connected to each other to make five or six membered cyclic and heterocyclic rings;

R⁵ and R⁶ are, at each occurrence, independently selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, C₃-C₁₀ cycloalkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;

R¹⁰ is a moiety selected from the group consisting of



wherein m' is 0, 1, 2, 3 or 4 and n' is 0, 1, 2, or 3;





R^{11} is, at each occurrence, independently selected from the group consisting of hydrogen, C_1 - C_{10} alkyl, C_3 - C_{10} cycloalkyl, C_2 - C_{10} alkenyl, C_3 - C_{10} cycloalkenyl, C_2 - C_{10} alkynyl, C_1 - C_{10} haloalkyl, $-OH$, $-OR^{13}$, C_1 - C_{10} alkoxy, C_3 - C_{10} cycloalkoxy, C_3 - C_{15} cycloalkylalkoxy, C_3 - C_{15} cycloalkylalkyl, $-NH_2$, $-N(R^{13})_2$, $-C(O)R^{13}$, $-C(O)OR^{13}$, $-C(O)N(R^{13})_2$, $-S(O)R^{13}$, $-S(O)_2R^{13}$, $-S(O)_2N(R^{13})_2$, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl, ~~any of which is optionally substituted~~;
















R^{12} is, at each occurrence, independently selected from the group consisting of hydrogen, C_1 - C_{10} alkyl, C_3 - C_{10} cycloalkyl, C_2 - C_{10} alkenyl, C_3 - C_{10} cycloalkenyl, C_2 - C_{10} alkynyl, C_1 - C_{10} haloalkyl, hydroxyl, $-OR^{14}$, $-C(O)R^{14}$, ~~$-R^{14}(R^{14})C(O)R^{14}$~~ , $-C(O)OR^{14}$, ~~$-R^{14}(R^{14})C(O)OR^{14}$~~ , $-CN$, $-NO_2$, $-NH_2$, $-N(R^{14})_2$, $-C(O)N(R^{14})_2$, ~~$-R^{14}(R^{14})C(O)N(R^{14})_2$~~ , $-S(O)R^{14}$, $-S(O)_2R^{14}$, $-S(O)_2N(R^{14})_2$, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl, ~~any of which is optionally substituted~~;













R^{13} is, at each occurrence, independently selected from the group consisting of hydrogen, C_1 - C_{10} alkyl, C_3 - C_{10} cycloalkyl, C_2 - C_{10} alkenyl, C_3 - C_{10} cycloalkenyl, C_2 - C_{10} alkynyl, C_1 - C_{10} haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl, ~~any of which is optionally substituted~~; and


R^{14} is, at each occurrence, independently selected from the group consisting of hydrogen, C_1 - C_8 alkyl optionally substituted with at least one hydroxyl or halogen; C_3 - C_7 cycloalkyl, C_2 - C_{10} alkenyl, C_3 - C_{10} cycloalkenyl, C_2 - C_{10} alkynyl, C_1 - C_{10} haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl and heterocyclyl, ~~any of which is optionally substituted~~.

~~3-2~~. The compound ~~as claimed in~~ ~~according to~~ claim 1 ~~or 2~~, having one of the formulae 1-352 ~~as shown in Table 1~~,












164




165




166




167




168




169




170




171




172




173




174




175




176




177




178







179





























180




























181



















**183****193****194****195**





























































preferably one of the formulae 15, 16, 31, 32, 44, 45, 47, 49, 54-57, 56, 60-87-66-69, 74, 77-80,
 89-91 103, 106, 107, 110, 111, 113, 116-135, 137-141, 139, 140, 143, 144, 147, 148, 152,
154, 157-159, 161-162-167, 171-182, 184-193, 196, 198, 199-202, 209-218, 221-227-225, 231,
248-260, 262-264, 267-269, 271-274, 280-293, 295-315, 317-318, 320-321, and 324, and 330
 as shown in Table 1,

and pharmaceutically acceptable salts thereof.

3. A compound having one of the formulae 17, 56, 58, 59, 66-69, 74, 77-80, 89-91, 108-115,
139, 140, 144, 162-181, 183, 193-195, 204-225, 265-329, and 331-352 as shown in claim 2,

preferably one of the formulae 56, 66-69, 74, 77-80, 89-91, 110, 111, 113, 139, 140, 144, 162-167, 171-181, 193, 209-218, 221-225, 267-269, 271-274, 280-293, 295-315, 317-318, 320-321, and 324.


4. The compound as claimed in according to any of claims 1—3~~claim 1~~, having ~~one of the formulae 47, 54, 177 and 185 as shown in Table 1,~~

~~and pharmaceutically acceptable salts thereof.~~

~~5. The compound according to any of claims 1—4, for use in the treatment of a bacterial infection.~~

~~6. The compound according to claim 5, wherein said bacterial infection is Tuberculosis.~~

5. A compound having the general formula Ib:



wherein

X, Y and Z are CH;


o is 1; n is 0; m is 1, 2, 3 or 4;

A is C=O;

W is NH;

R² is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C₁-C₁₀ alkyl, C₃-C₁₀ cycloalkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ haloalkyl, -OR⁵, C₁-C₁₀ alkoxy, C₃-C₁₀ cycloalkoxy, C₃-C₁₅ cycloalkylalkoxy, C₃-C₁₅ cycloalkylalkyl, -CN, -NO₂, -NH₂, -N(R⁵)₂, -C(O)R⁵, -C(O)OR⁵, -C(O)N(R⁵)₂, -SR⁵, -S(O)R⁵, -S(O)₂R⁵, -S(O)₂N(R⁵)₂, aryl, e.g. phenyl, benzyl, and heterocyclyl;

R¹⁰ is a moiety selected from the group consisting of



R¹¹ is, at each occurrence, independently selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, C₃-C₁₀ cycloalkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ haloalkyl, -OH, -OR¹³, C₁-C₁₀ alkoxy, C₃-C₁₀ cycloalkoxy, C₃-C₁₅ cycloalkylalkoxy, C₃-C₁₅ cycloalkylalkyl, -NH₂, -N(R¹³)₂, -C(O)R¹³, -C(O)OR¹³, -C(O)N(R¹³)₂, -S(O)R¹³, -S(O)₂R¹³, -S(O)₂N(R¹³)₂, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;

R¹² is, at each occurrence, independently selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, C₃-C₁₀ cycloalkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ haloalkyl, hydroxyl, -OR¹⁴, -C(O)R¹⁴, -CN, -NO₂, -NH₂, -N(R¹⁴)₂, -C(O)N(R¹⁴)₂, -S(O)R¹⁴, -S(O)₂R¹⁴, -S(O)₂N(R¹⁴)₂, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;

R¹³ is, at each occurrence, independently selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, C₃-C₁₀ cycloalkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl, and

R¹⁴ is, at each occurrence, independently selected from the group consisting of hydrogen, C₁-C₈ alkyl optionally substituted with at least one hydroxyl or halogen; C₃-C₇ cycloalkyl, C₂-C₁₀ alkenyl, C₃-C₁₀ cycloalkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl and heterocyclyl.

~~76.~~ A pharmaceutical composition comprising a compound as claimed in ~~according to~~ any of claims ~~1—6~~ 1—5, and a pharmaceutically acceptable carrier.

~~8. A method of treatment of a bacterial infection, in particular Tuberculosis, comprising the application of a suitable amount of a compound according to any of claims 1—6 or a pharmaceutical composition according to claim 7, to a person in need thereof.~~

~~9. A compound that competitively inhibits the specific binding of a compound according to any of claims 1—6.~~

~~10. A method of treatment of a bacterial infection, in particular Tuberculosis, comprising the application of a suitable amount of a compound, which compound is characterized by an ability to competitively inhibit the specific binding of a compound according to any of claims 1—6 or a pharmaceutical composition according to claim 7, to its target protein, to a person in need thereof.~~